Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Oct;32(4):504–507. doi: 10.1111/j.1365-2125.1991.tb03939.x

Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations.

D R Sohn 1, S G Shin 1, C W Park 1, M Kusaka 1, K Chiba 1, T Ishizaki 1
PMCID: PMC1368614  PMID: 1958447

Abstract

We examined metoprolol oxidation capacity in 218 unrelated, healthy Korean subjects using the 8 h urinary metabolic ratio (MR) of metoprolol to alpha-hydroxymetoprolol after an oral dose of 100 mg metoprolol tartrate. The results were compared with those from 295 Japanese and 107 mainland Chinese whose metoprolol oxidation capacities were assessed in a similar manner. The frequency of occurrence of poor metabolisers (PMs) was 0.5% (1/218) in the Korean, 0.7% (2/295) in the Japanese and 0% in the Chinese population. However, the respective mean (+/- s.d.) MRs (0.84 +/- 1.14 and 0.87 +/- 0.90) in the Korean and Japanese extensive metabolisers (EMs) were significantly (P less than 0.001) less than that in the Chinese EMs (2.81 +/- 2.35), and the mode of the distribution histogram and the probit plot of data for Chinese EMs were shifted to the right compared with those for Korean and Japanese EMs. The results indicate that Koreans, like Japanese and mainland Chinese, have a much lower frequency of the PM phenotype of debrisoquine/sparteine-type oxidation compared with that reported for Caucasian populations. Chinese EMs appear to have a lower capacity to metabolise metoprolol to alpha-hydroxymetoprolol compared with Korean or Japanese EMs.

Full text

PDF
504

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Eichelbaum M., Gross A. S. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. Pharmacol Ther. 1990;46(3):377–394. doi: 10.1016/0163-7258(90)90025-w. [DOI] [PubMed] [Google Scholar]
  2. Heim M., Meyer U. A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990 Sep 1;336(8714):529–532. doi: 10.1016/0140-6736(90)92086-w. [DOI] [PubMed] [Google Scholar]
  3. Horai Y., Ishizaki T., Ishikawa K. Metoprolol oxidation in a Japanese population: evidence for only one poor metaboliser among 262 subjects. Br J Clin Pharmacol. 1988 Dec;26(6):807–808. doi: 10.1111/j.1365-2125.1988.tb05325.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Horai Y., Ishizaki T., Kusaka M., Tsujimoto G., Hashimoto K. Simultaneous determination of metoprolol and alpha-hydroxymetoprolol in human plasma and urine by liquid chromatography with a preliminary observation on metoprolol oxidation in Japanese subjects. Ther Drug Monit. 1988;10(4):428–433. doi: 10.1097/00007691-198804000-00009. [DOI] [PubMed] [Google Scholar]
  5. Horai Y., Ishizaki T. N-acetylation polymorphism of dapsone in a Japanese population. Br J Clin Pharmacol. 1988 Apr;25(4):487–494. doi: 10.1111/j.1365-2125.1988.tb03333.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Horai Y., Ishizaki T. Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism. Ration Drug Ther. 1988 Jun;22(6):1–8. [PubMed] [Google Scholar]
  7. Horai Y., Nakano M., Ishizaki T., Ishikawa K., Zhou H. H., Zhou B. I., Liao C. L., Zhang L. M. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther. 1989 Aug;46(2):198–207. doi: 10.1038/clpt.1989.126. [DOI] [PubMed] [Google Scholar]
  8. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci. 1991 Mar;12(3):102–107. doi: 10.1016/0165-6147(91)90516-u. [DOI] [PubMed] [Google Scholar]
  9. Lou Y. C. Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metab Rev. 1990;22(5):451–475. doi: 10.3109/03602539008991447. [DOI] [PubMed] [Google Scholar]
  10. McGourty J. C., Silas J. H., Lennard M. S., Tucker G. T., Woods H. F. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol. 1985 Dec;20(6):555–566. doi: 10.1111/j.1365-2125.1985.tb05112.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Skoda R. C., Gonzalez F. J., Demierre A., Meyer U. A. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5240–5243. doi: 10.1073/pnas.85.14.5240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Steiner E., Iselius L., Alván G., Lindsten J., Sjöqvist F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther. 1985 Oct;38(4):394–401. doi: 10.1038/clpt.1985.193. [DOI] [PubMed] [Google Scholar]
  13. Yue Q. Y., Bertilsson L., Dahl-Puustinen M. L., Säwe J., Sjöqvist F., Johansson I., Ingelman-Sundberg M. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet. 1989 Oct 7;2(8667):870–870. doi: 10.1016/s0140-6736(89)93041-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES